Drugs for Laryngeal Benign Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 102)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Nicotinamide |
Approved, Investigational |
Phase 3 |
|
98-92-0 |
936 |
Synonyms:
3 Pyridinecarboxamide
3-Carbamoylpyridine
3-Pyridinecarboxamide
3-Pyridinecarboxylic acid amide
Acid amide
Amid kyseliny nikotinove
Amide PP
Aminicotin
Amixicotyn
Amnicotin
Astra brand OF niacinamide
Austrovit PP
b 3, Vitamin
b3, Vitamin
Benicot
beta-Pyridinecarboxamide
b-Pyridinecarboxamide
Delonin amide
Dipegyl
Dipigyl
Endobion
Enduramide
Factor PP
FREEDERM
Hansamid
Inovitan PP
Jenapharm brand OF niacinamide
Jenapharm, nicotinsäureamid
m-(Aminocarbonyl)pyridine
Mediatric
Merck brand OF niacinamide
NAM
Nandervit-N
Niacevit
Niacin
Niacinamide
Niacinamide astra brand
Niacinamide jenapharm brand
Niacinamide merck brand
Niacinamide pharmagenix brand
Niamide
NIATIN
Niavit PP
NICAM
Nicamide
Nicamina
Nicamindon
Nicasir
Nicobion
Nicofort
Nicogen
Nicomidol
|
Nicosan 2
Nicosylamide
Nicota
Nicotamide
Nicotilamide
Nicotililamido
Nicotinamid
Nicotinamida
Nicotinamide
Nicotinamidum
Nicotinate amide
Nicotine acid amide
Nicotine amide
Nicotinic acid amide
Nicotinic amide
Nicotinsaeureamid
Nicotinsaureamid
Nicotinsäureamid jenapharm
Nicotol
Nicotylamide
Nicotylamidum
Nicovel
Nicovit
Nicovitina
Nicovitol
Nicozymin
Nictoamide
Niko-tamin
Nikotinamid
Nikotinsaeureamid
Niocinamide
Niozymin
NSC-13128
NSC-27452
Papulex
Pelmin
Pelmine
Pelonin amide
Pharmagenix brand OF niacinamide
PP-Faktor
Propamine a
PYRIDINE-3-CARBOXAMIDE
Pyridine-3-carboxylic acid amide
Savacotyl
Vi-nicotyl
Vi-noctyl
Vitamin b 3
Vitamin b3
Vitamin PP
Witamina PP
Î’-pyridinecarboxamide
|
|
2 |
|
Cefazolin |
Approved |
Phase 3 |
|
25953-19-9 |
33255 |
Synonyms:
(6R,7R)-3-{[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl}-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
(6R,7R)-3-{[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl}-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6R,7R)-3-{[(5-methyl-1,3,4-thiadiazol-2-yl)sulphanyl]methyl}-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
(6R,7R)-3-{[(5-methyl-1,3,4-thiadiazol-2-yl)sulphanyl]methyl}-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Ancef
Cefamedin
Cefamezin
Cefamezine
CEFAZOLIN
Cefazolin sodium
Cefazolina
Cefazoline
Cefazolinum
Cephamezine
|
Cephazolidin
Cephazolin
Cephazolin sodium
Cephazolin, sodium
Cephazoline
CEZ
Gramaxin
J01DB04
Kefzol
SK&F-41558
Sodium cephazolin
Sodium, cefazolin
Sodium, cephazolin
Totacef
|
|
3 |
|
Cisplatin |
Approved |
Phase 2, Phase 3 |
|
15663-27-1 |
2767 5702198 441203 |
Synonyms:
Abiplatin
Biocisplatinum
Briplatin
CACP
Carboquone
CDDP
Cis Pt II
cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
CIS-DIAMMINEDICHLOROPLATINUM(II)
Cismaplat
CISPLATIN
Cisplatine
cisplatino
CISPLATINUM
CIS-PLATINUM II
Cisplatyl
Citoplationo
CPDC
CPDD
DDP
DDPT
|
Diamminedichloroplatinum
INT230-6 COMPONENT CISPLATIN
INT-230-6 COMPONENT CISPLATIN
Lederplatin
Neoplatin
NSC-119875
Plastin
Platamine
Platiblastin
Platidiam
Platinex
PLATINOL
PLATINOL-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
|
|
4 |
|
Docetaxel |
Approved, Investigational |
Phase 2, Phase 3 |
|
114977-28-5 |
148124 |
Synonyms:
CKD-810
Docecad®|docetaxel anhydrous|EmDOC|Taxotere®
DOCEFREZ
DOCETAXEL
Docetaxel anhydrous
Docetaxel hydrate
Docetaxel trihydrate
Docetaxel, trihydrate
Docetaxol
N Debenzoyl N tert butoxycarbonyl 10 deacetyltaxol
|
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol
NSC-628503
RP-56976
TAXCEUS
Taxoltere metro
Taxotere
TXL
XRP6976
|
|
5 |
|
Carboplatin |
Approved |
Phase 2, Phase 3 |
|
41575-94-4 |
10339178 38904 |
Synonyms:
Blastocarb
Carboplat
CARBOPLATIN
Carboplatine
Carboplatino
Carbosin
Carbotec
Cbdca
CIS-(1,1-CYCLOBUTANEDICARBOXYLATO)DIAMMINEPLATINUM(II)
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM(II)
|
Ercar
JM 8
JM8
JM-8
Nealorin
Neocarbo
NSC-201345
NSC-241240
PARAPLATIN
Paraplatin-AQ
Ribocarbo
|
|
6 |
|
Atezolizumab |
Approved, Investigational |
Phase 2, Phase 3 |
|
1380723-44-3 |
|
Synonyms:
ANTI-PDL1
ANTI-PD-L1
ATEZOLIZUMAB
MPDL3280A
|
MPDL-3280A
RG-7446
TECENTRIQ
|
|
7 |
|
Bevacizumab |
Approved, Investigational |
Phase 2, Phase 3 |
|
216974-75-3 |
135329020 |
Synonyms:
12-IGG1
ANTIVEGF
Anti-VEGF Humanized Monoclonal Antibody
Anti-VEGF monoclonal antibody
AVA-1
AVASTIN
Bevacizumab
BEVACIZUMAB BETA
bevacizumab-awwb
|
BI 695502
BS-503A
FKB-238
HLX04
HLX-04
R-435
RG-435
RHUMAB-
rhuMAb-VEGF
|
|
8 |
|
Sucralfate |
Approved |
Phase 3 |
|
54182-58-0 |
|
Synonyms:
ANTEPSIN
CARAFATE
Hexadeca-μ-hydroxytetracosahydroxy[μ8-[1,3,4,6-tetra-O-sulfo-β-Dfructofuranosyl-α-D-glucopyranoside tetrakis(hydrogen sulfato)8-)]]hexadecaaluminum
Octaaluminium(3+) ion (2R,3S,4S,5R)-2,4-bis(sulfonatooxy)-5-[(sulfonatooxy)methyl]-5-{[(2S,3R,4S,5R,6R)-3,4,5-tris(sulfonatooxy)-6-[(sulfonatooxy)methyl]oxan-2-yl]oxy}oxolan-3-yl sulfuric acid hexadecahydroxide
Octaaluminium(3+) ion (2R,3S,4S,5R)-2,4-bis(sulphonatooxy)-5-[(sulphonatooxy)methyl]-5-{[(2S,3R,4S,5R,6R)-3,4,5-tris(sulphonatooxy)-6-[(sulphonatooxy)methyl]oxan-2-yl]oxy}oxolan-3-yl sulphate hexadecahydroxide
Octaaluminium(3+) ion (2R,3S,4S,5R)-2,4-bis(sulphonatooxy)-5-[(sulphonatooxy)methyl]-5-{[(2S,3R,4S,5R,6R)-3,4,5-tris(sulphonatooxy)-6-[(sulphonatooxy)methyl]oxan-2-yl]oxy}oxolan-3-yl sulphuric acid hexadecahydroxide
Sucralfat
|
Sucralfate
SUCRALFATE HYDRATE
Sucralfato
Sucralfatum
Sucralfic acid
ULCERLMIN
|
|
9 |
|
Durvalumab |
Approved, Investigational |
Phase 2, Phase 3 |
|
1428935-60-7 |
|
Synonyms:
|
10 |
|
Niacin |
Approved, Investigational, Nutraceutical |
Phase 3 |
|
59-67-6 |
938 |
Synonyms:
[<sup>3</sup>H]-nicotinic acid
3 Pyridinecarboxylic acid
3-CARBOXYLPYRIDINE
3-CARBOXYPYRIDINE
3-PICOLINIC ACID
3-PYRIDINECARBOXYLATE
3-PYRIDINECARBOXYLIC ACID
3-PYRIDYLCARBOXYLATE
3-PYRIDYLCARBOXYLIC ACID
ACIDE NICOTINIQUE
ACIDO NICOTINICO
ácido nicotínico
ACIDUM NICOTINICUM
AKOTIN
Aluminum salt, niacin
ANTI-PELLAGRA VITAMIN
APELAGRIN
beta-Pyridinecarboxylate
BETA-PYRIDINECARBOXYLIC ACID
b-Pyridinecarboxylate
b-Pyridinecarboxylic acid
DASKIL
EFACIN
ENDURACIN
Hydrochloride, niacin
INDURACIN
LINIC
Lithium nicotinate
m-Pyridinecarboxylate
M-PYRIDINECARBOXYLIC ACID
NIAC
NIACIN
Niacin aluminum salt
Niacin ammonium salt
Niacin calcium salt
Niacin cobalt (2+) salt
Niacin copper (2+) salt
Niacin hydrochloride
Niacin iron (2+) salt
Niacin lithium salt
Niacin lithium salt, hemihydrate
Niacin magnesium salt
Niacin manganese (2+) salt
Niacin potassium salt
Niacin sodium salt
Niacin tartrate
NIACIN TD
Niacin tosylate
Niacin zinc salt
niacin|nicotinate|vitamin B<sub>3</sub>|vitamin PP
Niacina
NIACINE
|
NIACOR
NIASPAN
NIASPAN ER
NIASPAN TITRATION STARTER PACK
NICACID
NICAMIN
NICANGIN
Nico 400
Nico400
Nico-400
NICOBID
NICOCAP
NICODELMINE
NICOLAR
NICONACID
NICOSAN 3
NICO-SPAN
NICOTINATE
Nicotinate, lithium
NICOTINIC ACID
NICOTINIPCA
NICYL
NIKOTINSAEURE
Nikotinsäure
NSC-169454
NYCLIN
P.P. FACTOR
PELLAGRA PREVENTIVE FACTOR
PELLAGRIN
PELONIN
PEVITON
Potassium salt, niacin
PP FACTOR
PYRIDINE-3-CARBOXYLIC ACID
Pyridine-b-carboxylate
Pyridine-b-carboxylic acid
Pyridine-beta-carboxylate
PYRIDINE-BETA-CARBOXYLIC ACID
Pyridine-β-carboxylate
PYRIDINE-Î’-CARBOXYLIC ACID
SIMCOR
SLO-NIACIN
Sodium salt, niacin
Tartrate, niacin
TINIC
Tosylate, niacin
VITAMIN B3
VITAMIN PP
WAMPOCAP
Î’-pyridinecarboxylate
Î’-PYRIDINECARBOXYLIC ACID
|
|
11 |
|
Vitamin B3 |
|
Phase 3 |
|
|
|
12 |
|
Nicotinic Acids |
|
Phase 3 |
|
|
|
13 |
|
Anti-Bacterial Agents |
|
Phase 3 |
|
|
|
14 |
|
Anti-Infective Agents |
|
Phase 3 |
|
|
|
15 |
|
Antimitotic Agents |
|
Phase 2, Phase 3 |
|
|
|
16 |
|
Tubulin Modulators |
|
Phase 2, Phase 3 |
|
|
|
17 |
|
Angiogenesis Inhibitors |
|
Phase 2, Phase 3 |
|
|
|
18 |
|
Endothelial Growth Factors |
|
Phase 2, Phase 3 |
|
|
|
19 |
|
Mitogens |
|
Phase 2, Phase 3 |
|
|
|
20 |
|
Aloe |
|
Phase 3 |
|
|
|
21 |
|
Anti-Ulcer Agents |
|
Phase 3 |
|
|
|
22 |
|
Antacids |
|
Phase 3 |
|
|
|
23 |
|
Gastrointestinal Agents |
|
Phase 3 |
|
|
|
24 |
|
Antineoplastic Agents, Immunological |
|
Phase 2, Phase 3 |
|
|
|
25 |
|
Immunologic Factors |
|
Phase 2, Phase 3 |
|
|
|
26 |
|
Immunoglobulins, Intravenous |
|
Phase 2, Phase 3 |
|
|
|
27 |
|
Immunoglobulins |
|
Phase 2, Phase 3 |
|
|
|
28 |
|
Immunoglobulin G |
|
Phase 2, Phase 3 |
|
|
|
29 |
|
Antibodies, Monoclonal |
|
Phase 2, Phase 3 |
|
|
|
30 |
|
Antibodies |
|
Phase 2, Phase 3 |
|
|
|
31 |
|
Raspberry |
Approved |
Phase 1, Phase 2 |
|
|
|
32 |
|
Hyaluronic acid |
Approved, Vet_approved |
Phase 2 |
|
9004-61-9 |
53477741 |
Synonyms:
(2S,3S,4R,5R,6R)-3-[(2S,3R,4R,5S,6R)-3-Acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate
(2S,3S,4R,5R,6R)-3-[(2S,3R,4R,5S,6R)-3-Acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid
(2S,3S,4R,5R,6R)-3-{[(2S,3R,4R,5S,6R)-4,5-dihydroxy-3-[(1-hydroxyethylidene)amino]-6-(hydroxymethyl)oxan-2-yl]oxy}-4,5,6-trihydroxyoxane-2-carboxylate
2-Acetamido-2-deoxy-b-D-gluco-hexopyranosyl-(1->4)-b-D-gluco-hexopyranuronate
2-Acetamido-2-deoxy-b-D-gluco-hexopyranosyl-(1->4)-b-D-gluco-hexopyranuronic acid
2-Acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->4)-beta-D-gluco-hexopyranuronate
|
2-Acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->4)-beta-D-gluco-hexopyranuronic acid
2-Acetamido-2-deoxy-β-D-gluco-hexopyranosyl-(1->4)-β-D-gluco-hexopyranuronate
2-Acetamido-2-deoxy-β-D-gluco-hexopyranosyl-(1->4)-β-D-gluco-hexopyranuronic acid
Hyaluronan
Hyaluronate
WURCS=2.0/2,2,1/[a2122a-1b_1-5][a2122h-1b_1-5_2*ncc/3=o]/1-2/a4-b1
|
|
33 |
|
Sargramostim |
Approved, Investigational |
Phase 2 |
|
123774-72-1 |
|
Synonyms:
B1 61.012
B1-61012
LEUKINE
RECOMBINANT GM-CSF
Recombinant human granulocyte-macrophage colony stimulating factor
|
rGM-CSF
RHU GM-CSF
RHU-GM-CSF
SARGRAMOSTIM
|
|
34 |
|
Celecoxib |
Approved, Investigational |
Phase 2 |
|
169590-42-5 |
2662 |
Synonyms:
4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide
4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENE-1-SULFONAMIDE
4-[5-(4-METHYLPHENYL)-3-TRIFLUOROMETHYL)-1H-PYRAZOL-YL]BENZENESULFONAMIDE
CELEBRA
Celebrex
CELECOX
Celecox®|Elyxyb® (DFN-15; oral solution)|Onsenal®|SC-58635|SC58635
Celecoxib
Célécoxib
|
Celecoxibum
Celocoxib
DFN15
DFN-15
Onsenal
p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulphonamide
SC-58635
|
|
35 |
|
Cemiplimab |
Approved, Investigational |
Phase 2 |
|
1801342-60-8 |
|
Synonyms:
CEMIPLIMAB
CEMIPLIMAB-RWLC
cemiplimab-rwlc|Libtayo®|REGN-2810|REGN2810|SAR-439684|SAR439684
|
LIBTAYO
REGN2810
REGN-2810
|
|
36 |
|
Paclitaxel |
Approved, Vet_approved |
Phase 2 |
|
33069-62-4 |
36314 |
Synonyms:
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7 Epi taxol
7-Epipaclitaxel
7-Epi-paclitaxel
7-epipaclitaxel|Abraxane® (albumin-bound suspension)|Taxol®
7-Epitaxol
7-Epi-taxol
ABI-007
ABRAXANE
Anzatax
BMS 181339-01
BMS-181339-01
Bris taxol
CAPXOL
CYCLOPAX
DHP 107
|
EBETAXEL
Epitaxol
GENETAXYL
GENEXOL
INTAXEL
LIPOPAC
MBT 0206
MITOTAX
NK 105
NSC-125973
Onxol
PACITAXEL
PACLITAXEL
Paclitaxel, (4 alpha)-isomer
Paxceed
Paxene
PLAXICEL
Praxel
QW-8184
TAXALBIN
TAXOL
TAXOL 100
Taxol a
Taxol, bris
Vascular Wrap
Xorane
YEWTAXAN
|
|
37 |
|
Nivolumab |
Approved |
Phase 2 |
|
946414-94-4 |
|
Synonyms:
BMS-936558
BMS-936558|MDX-1106|ONO-4538|Opdivo®
MDX-1106
|
NIVOLUMAB
ONO-4538
OPDIVO
|
|
38 |
|
Doxepin |
Approved, Investigational |
Phase 2 |
|
1668-19-5 |
667468 667477 |
Synonyms:
[<sup>11</sup>C]-doxepin
3-Dibenz[b,e]oxepin-11(6H)-ylidene-N,N-dimethyl-1-propanamine
Adapin
Apo doxepin
Apo-doxepin
ApoDoxepin
Aponal
Curatin
Deptran
Deptran®|P-3693A|Sinequan®
Desidox
Doneurin
Doxepia
DOXEPIN
Doxepin beta
Doxepin Hcl
Doxepin hydrochloride
Doxepin hydrochloride, cis-trans isomer mixture (approximately 1:5)
Doxepin RPH
Doxepin, Hydrochloride
|
Doxepina
Doxepina [INN-Spanish]
Doxepine
Doxepin-RPH
Doxepinum
Doxepinum [INN-Latin]
Espadox
Hydrochloride, doxepin
Mareen
Novo doxepin
Novo-doxepin
P-3693A
Prudoxin
Quitaxon
SINEPIN
Sinequan
Sinquan
Triadapin
Xepin
Zonalon
|
|
39 |
|
Histamine |
Approved, Investigational |
Phase 2 |
|
51-45-6 |
774 |
Synonyms:
1H-Imidazole-4-ethanamine
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(3H-Imidazol-4-yl)ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-Imidazolyl)ethylamine
2-Imidazol-4-ylethylamine
2-Imidazol-4-yl-ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-Imidazoleethylamine
5-Imidazoleethylamine
|
beta-Aminoethylglyoxaline
beta-Aminoethylimidazole
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
b-Imidazolyl-4-ethylamine
Eramin
Ergamine
Ergotidine
Histamine
HSM
Imidazole-4-ethylamine
NSC-33792
Î’-imidazolyl-4-ethylamine
|
|
40 |
|
Diphenhydramine |
Approved, Investigational |
Phase 2 |
|
147-24-0, 58-73-1 |
3100 |
Synonyms:
[2-(DIPHENYLMETHOXY)ETHYL]DIMETHYLAMINE
2-(Benzhydryloxy)-N,N-dimethylethylamine
2-Diphenylmethoxy-N,N-demthylethanamine
2-Diphenylmethoxy-N,N-dimethylethylamine
a-(2-Dimethylaminoethoxy)diphenylmethane
Alledryl
Allerdryl
Allergan
Allergina
alpha-(2-Dimethylaminoethoxy)diphenylmethane
ANTITUSSIVE
b-Dimethylaminoethanol diphenylmethyl ether
b-Dimethylaminoethyl benzhydryl ether
BELDIN
BELIX
Benadryl
BENADRYL PRESERVATIVE FREE
Benadryl®|benzhydramine|dimehydrinate
Bendylate
Benhydramin
Benylin
Benzantin
Benzhydramine
beta-Dimethylaminoethanol diphenylmethyl ether
beta-Dimethylaminoethyl benzhydryl ether
CALADRYL
Citrate, diphenhydramine
COLTEX
DIBENIL
Difenhidramina
Difenhydramine
Dimedrol
Dimedrolum
DIMEHYDRINATE
Dimethylamine benzhydryl ester
Diphamine
Diphantine
|
DIPHEN
DIPHENHYDRAMINE
Diphenhydramine citrate
Diphenhydramine citrate (1:1)
DIPHENHYDRAMINE HCL
Diphenhydramine hydrochloride
DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE
Diphenhydraminum
Diphenylhydramin
Diphenylhydramine
Dobacen
Dormin
DREEMON
DYTUSS
FEDRIL
GPPE COUGH EXPECT PAED
GPPE ORAL SOLN
HISTERGAN
HYDRAMINE
Hydrochloride, diphenhydramine
MEDINEX
N-(2-(Diphenylmethoxy)ethyl)-N,N-dimethylamine
NIGHTCALM
NSC-33299
NYTOL
NYTOL ONE-A-NIGHT
O-Benzhydryldimethylaminoethanol
PAXIDORM
Restamin
SILPHEN
SLEEPIA
SYNTEDRIL
TIXYLIX CATARRH
VICKS FORMULA 44
Α-(2-dimethylaminoethoxy)diphenylmethane
Î’-dimethylaminoethanol diphenylmethyl ether
Î’-dimethylaminoethyl benzhydryl ether
|
|
41 |
|
Promethazine |
Approved, Investigational |
Phase 2 |
|
60-87-7 |
4927 |
Synonyms:
(2-Dimethylamino-2-methyl)ethyl-N-dibenzoparathiazine
10-(2-Dimethylaminopropyl)phenothiazine
10-[2-(Dimethylamino)propyl]phenothiazine
Atosil
Diphergan
Diprazin
Hydrochloride, promethazine
Isopromethazine
Lilly 1516
N-(2'-Dimethylamino-2'-methyl)ethylphenothiazine
N,N,alpha-Trimethyl-10H-phenothiazine-10-ethanamine
N,N,a-Trimethyl-10H-phenothiazine-10-ethanamine
N,N,Α-trimethyl-10H-phenothiazine-10-ethanamine
NSC-30321
Phenargan
Phenergan
Phenergan®|Sominex®
Phensedyl
Pipolfen
Pipolphen
Proazaimine
Proazamine
|
Promazinamide
Promet
Prometazin
Prometazina
Prometazine
PROMETHACON
Promethazin
PROMETHAZINE
Promethazine hydrochloride
Promethazinum
PROMETHEGAN
Promethiazine
Promezathine
Prothazin
Prothazine
Pyrethia
Remsed
RP-3277
Rumergan
SOMINEX
ZIPAN-25
ZIPAN-50
|
|
42 |
|
Cetuximab |
Approved |
Phase 2 |
|
205923-56-4 |
|
Synonyms:
ABP-494
ANTI EGFR
C225
C-225
C225|Erbitux®|IMC-225|IMC-C225
CETUXIMAB
Cétuximab
CETUXIMAB (GENETICAL RECOMBINATION)
|
Cetuximabum
CMAB009
CMAB-009
ERBITUX
IMC-225
IMC-C225
MOAB C225
|
|
43 |
|
Fluorouracil |
Approved |
Phase 2 |
|
51-21-8 |
3385 |
Synonyms:
5 Fluorouracil
5 Fluorouracil biosyn
5 FU
5 FU lederle
5 FU medac
5 HU hexal
5.F.U.
5-Fluoracil
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluracil
5FU
5-FU
5-FU lederle
5-FU medac
5-HU hexal
ACCUSITE
ACTIKERALL
Adrucil
Allergan brand OF fluorouracil
Arumel
Biosyn brand OF fluorouracil
Carac
Carzonal
CSP Brand OF fluorouracil
Dakota brand OF fluorouracil
Dakota, fluorouracile
Dermatech brand OF fluorouracil
Dermik brand OF fluorouracil
Effluderm
Efudex
Efudix
Efurix
Ferrer brand OF fluorouracil
Fluoro Uracil
Fluoro uracile icn
Fluoroblastin
Fluoroplex
Fluorouracil
Fluorouracil gry
Fluorouracil mononitrate
Fluorouracil monopotassium salt
Fluorouracil monosodium salt
Fluorouracil potassium salt
FLUORO-URACIL ROCHE
Fluorouracil teva brand
|
Fluorouracile dakota
Fluoro-uracile icn
Fluorouracil-gry
Fluorouracilo
Fluorouracilo ferrer far
Fluorouracilum
Fluoruracil
Fluouracil
Fluracedyl
FLURACIL
Fluracilum
Fluri
Fluril
Fluro Uracil
Flurodex
Flurouracil
Ftoruracil
FU
Gry brand OF fluorouracil
Haemato brand OF fluorouracil
Haemato fu
Haemato-fu
Hexal brand OF fluorouracil
ICN brand OF fluorouracil
Kecimeton
Medac brand OF fluorouracil
Neocorp brand OF fluorouracil
Neofluor
NSC-19893
Onkofluor
Onkoworks brand OF fluorouracil
Pharmachemie brand OF fluorouracil monosodium salt
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
Ribosepharm brand OF fluorouracil
Riemser brand OF fluorouracil
RO-29757
RO-2-9757
Roche brand OF fluorouracil
Teva brand OF fluorouracil
Timazin
TOLAK
Ulup
URF
|
|
44 |
|
Aspartic acid |
Approved, Nutraceutical |
Phase 1, Phase 2 |
|
56-84-8 |
5960 |
Synonyms:
(+)-Aspartate
(+)-Aspartic acid
(+-)-Aspartic acid
(2S)-2-AMINOBUTANEDIOIC ACID
(2S)-2-AMINOSUCCINIC ACID
(2S)-Aspartate
(2S)-Aspartic acid
(L)-Aspartate
(L)-Aspartic acid
(R)-2-Aminosuccinate
(R,S)-Aspartic acid
(S)-(+)-Aspartate
(S)-(+)-Aspartic acid
(S)-2-Aminobutanedioate
(S)-2-Aminobutanedioic acid
(S)-2-Aminosuccinate
(S)-2-Aminosuccinic acid
(S)-Aminobutanedioate
(S)-Amino-butanedioate
(S)-Aminobutanedioic acid
(S)-Amino-butanedioic acid
(S)-Aspartate
(S)-Aspartic acid
[<sup>3</sup>H]-L-aspartate|[<sup>3</sup>H]-L-aspartic acid
2-Amino-3-methylsuccinate
2-Amino-3-methylsuccinic acid
2-Aminosuccinate
2-Aminosuccinic acid
ácido aspártico
Acidum asparticum
alpha-Aminosuccinate
alpha-Aminosuccinic acid
Aminosuccinate
Ammonium aspartate
Asp
Asparagate
Asparagic acid
Asparaginate
Asparaginic acid
Asparatate
ASPARTate
Aspartate magnesium hydrochloride
Aspartate, ammonium
Aspartate, calcium
Aspartate, dipotassium
Aspartate, disodium
Aspartate, magnesium
Aspartate, monopotassium
Aspartate, monosodium
Aspartate, potassium
Aspartate, sodium
|
ASPARTIC ACID
Aspartic acid, ammonium salt
Aspartic acid, calcium salt
Aspartic acid, dipotassium salt
Aspartic acid, disodium salt
Aspartic acid, hydrobromide
Aspartic acid, hydrochloride
Aspartic acid, magnesium (1:1) salt, hydrochloride, trihydrate
Aspartic acid, magnesium (2:1) salt
Aspartic acid, magnesium-potassium (2:1:2) salt
Aspartic acid, monopotassium salt
Aspartic acid, monosodium salt
Aspartic acid, potassium salt
Aspartic acid, sodium salt
Calcium aspartate
D
Dipotassium aspartate
Disodium aspartate
FEMA NO. 3656
H-Asp-OH
Hydrobromide aspartic acid
Hydrochloride aspartic acid
Hydrochloride, aspartate magnesium
L Aspartate
L Aspartic acid
L-(+)-Aspartate
L-(+)-Aspartic acid
L-Aminosuccinate
L-Aminosuccinic acid
L-Asp
L-Asp|L-aspartate
L-Asparagate
L-Asparagic acid
L-Asparaginate
L-Asparaginic acid
L-Asparaginsaeure
L-Asparaginsäure
L-Aspartate
L-Aspartic acid
Magnesiocard
Magnesium aspartate
MG 5 Longoral
MG5Longoral
MG-5-Longoral
Monopotassium aspartate
Monosodium aspartate
NSC-3973
Poly-DL-succinimide
Polysuccinimide
Potassium aspartate
Sodium aspartate
|
|
45 |
|
Arginine |
Approved, Investigational, Nutraceutical |
Phase 1, Phase 2 |
|
74-79-3 |
6322 |
Synonyms:
(2S)-2-Amino-5-(carbamimidamido)pentanoate
(2S)-2-Amino-5-(carbamimidamido)pentanoic acid
(2S)-2-AMINO-5-(DIAMINOMETHYLIDENEAMINO)PENTANOIC ACID
(2S)-2-AMINO-5-[(DIAMINOMETHYLIDENE)AMINO]PENTANOIC ACID
(2S)-2-Amino-5-guanidinopentanoate
(2S)-2-Amino-5-guanidinopentanoic acid
(2S)-2-AMINO-5-GUANIDINO-PENTANOIC ACID
(S)-2-Amino-5-[(aminoiminomethyl)amino]pentanoate
(S)-2-Amino-5-[(aminoiminomethyl)amino]-pentanoate
(S)-2-Amino-5-[(aminoiminomethyl)amino]pentanoic acid
(S)-2-Amino-5-[(aminoiminomethyl)amino]-pentanoic acid
(S)-2-Amino-5-guanidinopentanoate
(S)-2-Amino-5-guanidinopentanoic acid
(S)-2-Amino-5-guanidinovalerate
(S)-2-Amino-5-guanidinovaleric acid
2-Amino-5-guanidinovalerate
2-Amino-5-guanidinovaleric acid
5-[(Aminoiminomethyl)amino]-L-norvaline
Arg
Arginina
Arginine
|
Arginine hydrochloride
Arginine, L isomer
Arginine, L-isomer
DL Arginine acetate, monohydrate
DL-Arginine acetate, monohydrate
Hydrochloride, arginine
L Arginine
L-(+)-Arginine
L-a-Amino-D-guanidinovalerate
L-a-Amino-D-guanidinovaleric acid
L-alpha-Amino-delta-guanidinovalerate
L-alpha-Amino-delta-guanidinovaleric acid
L-Arg
L-Arginin
L-ARGININE
L-Isomer arginine
Monohydrate DL-arginine acetate
N5-(Aminoiminomethyl)-L-ornithine
NSC-206269
R
|
|
46 |
|
Glycine |
Approved, Nutraceutical, Vet_approved |
Phase 1, Phase 2 |
|
56-40-6 |
750 |
Synonyms:
[<sup>14</sup>C]-glycine
2-Aminoacetate
2-Aminoacetic acid
Acid, aminoacetic
Aciport
Aminoacetate
Amino-acetate
Amino-acetic acid
AMINOACETIC ACID
AMINOESSIGSAEURE
AMINOESSIGSÄURE
Aminoethanoate
AMINOETHANOIC ACID
Calcium salt glycine
Cobalt salt glycine
Copper salt glycine
FEMA NO. 3287
G
Glicina
Glicoamin
GLY
GLYCIN
GLYCINE
Glycine carbonate (1:1), monosodium salt
Glycine carbonate (2:1), monolithium salt
Glycine carbonate (2:1), monopotassium salt
Glycine carbonate (2:1), monosodium salt
Glycine hydrochloride
Glycine hydrochloride (2:1)
Glycine phosphate
|
Glycine phosphate (1:1)
Glycine sulfate (3:1)
Glycine, calcium salt
Glycine, calcium salt (2:1)
Glycine, cobalt salt
Glycine, copper salt
Glycine, monoammonium salt
Glycine, monopotasssium salt
Glycine, monosodium salt
Glycine, sodium hydrogen carbonate
GLYCOCOLL
GLYCOLIXIR
Glycosthene
GLYKOKOLL
GLYZIN
Gyn-hydralin
H2N-CH2-COOH
HGLY
Hydrochloride, glycine
LEIMZUCKER
Monoammonium salt glycine
Monopotasssium salt glycine
Monosodium salt glycine
NSC-25936
Padil
Phosphate, glycine
Salt glycine, monoammonium
Salt glycine, monosodium
جلايسين
|
|
47 |
|
Etanidazole |
Investigational |
Phase 2 |
|
22668-01-5 |
3276 |
Synonyms:
Etanidazol
Etanidazole
Etanidazolum
N-(2-Hydroxyethyl)-1-(2-nitro-1-imidazolyl)acetamide
|
N-(2-Hydroxyethyl)-2-nitro-1H-imidazole-1-acetamide
N-(2-Hydroxyethyl)-2-nitroimidazole-1-acetamide
Radinyl
|
|
48 |
|
(-)-Gossypol |
Investigational |
Phase 2 |
|
303-45-7, 90141-22-3 |
3503 |
Synonyms:
(-)-GOSSYPOL
(+)-Gossypol
(+-)-Gossypol
(+/-)-gossypol
(R)-(-)-Gossypol
(r)-2,2'-bis(8-formyl-1,6,7-trihydroxy-5-isopropyl-3-methylnaphthalene)
(R)-Gossypol
BL-193
Dipotassium salt, gossypol
Gossypol
Gossypol dipotassium salt
Gossypol from cotton seeds
|
Gossypol r-form
Gossypol sodium salt
Gossypol, (-)-isomer
Gossypol, (+)-isomer
Gossypol, (+-)-isomer
NSC-56817
NSC-624336
Pogosin
R-(-)-gossypol
Racemic-gossypol
Sodium salt, gossypol
Tash 1
|
|
49 |
|
Molgramostim |
Investigational |
Phase 2 |
|
99283-10-0 |
|
Synonyms:
|
MOLGRAMOSTIM (GENETICAL RECOMBINATION)
SCH-39300
|
|
50 |
|
Pyrazole |
Experimental |
Phase 2 |
|
288-13-1 |
|
Synonyms:
1,2-Diazole
1H-Pyrazol
1H-PYRAZOLE
|
|
|
Interventional clinical trials:
(show top 50)
(show all 80)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
the Comparison of Voice Quality in Early Laryngeal Cancer Between Surgery and Radiotherapy |
Unknown status |
NCT00497588 |
Phase 3 |
|
2 |
A Multicentre, Randomised, Phase III Clinical Trial Comparing Accelerated Radiotherapy With Accelerated Radiotherapy Plus Carbogen and Nicotinamide (ARCON) in Clinical Stage T2-4 Laryngeal Carcinoma. |
Completed |
NCT00147732 |
Phase 3 |
|
3 |
Double Blind Randomised Study of 2 Days and 5 Days Cefazolin Prophylactic Method in Laryngeal Oncologic Surgery |
Completed |
NCT00467948 |
Phase 3 |
cefazolin |
4 |
A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers |
Recruiting |
NCT05063552 |
Phase 2, Phase 3 |
Carboplatin;Cisplatin;Docetaxel |
5 |
Effects of Oral Aloe Vera Juice on Chemotherapy and Radiation-induced Oral Mucositis and Esophagitis: a Single-blind Randomized Controlled Trial |
Recruiting |
NCT05369234 |
Phase 3 |
Carafate |
6 |
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin |
Active, not recruiting |
NCT03258554 |
Phase 2, Phase 3 |
|
7 |
Phase II Organ Preservation Trial Using Cisplatin Concomitant With Radiation Therapy in Advanced Laryngeal Cancer Patients Who Have Responded to Induction Chemotherapy With Taxotere, Cisplatin, and 5-Fluorouracil (TPF) |
Unknown status |
NCT01073683 |
Phase 2 |
Taxotere (Docetaxel), Cisplatin, 5FU |
8 |
Resistance Training During Radiation Therapy for Pharyngeal or Laryngeal Cancer |
Completed |
NCT00827164 |
Phase 2 |
|
9 |
Clinical Outcomes Modeling for Laryngectomy Surgery Patients and Efficacy of Hyperbaric Oxygen Therapy |
Completed |
NCT00026975 |
Phase 2 |
|
10 |
Concomitant Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Bio-selection For Organ Preservation In Patients With Advanced Laryngeal Cancer |
Completed |
NCT01633541 |
Phase 2 |
AT-101;Docetaxel;Cisplatin;Carboplatin |
11 |
Combination of Cryosurgey and NK Immunotherapy for Recurrent Laryngeal Cancer |
Completed |
NCT02849314 |
Phase 1, Phase 2 |
|
12 |
Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis |
Completed |
NCT01806675 |
Phase 1, Phase 2 |
18F-fludeoxyglucose (18F-FDG);18F-FPPRGD2 |
13 |
Food-Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer |
Completed |
NCT01469429 |
Phase 1, Phase 2 |
chemoprevention |
14 |
Injection Thyroplasty During Transoral Laser Microsurgery for Early Glottic Cancer: Single-blinded Randomized Controlled Trial |
Completed |
NCT04525066 |
Phase 2 |
Hyaluronic acid |
15 |
A Phase II, Randomized, Open-Label, Single Center Study In Patients With Advanced Head And Neck Cancer To Investigate Efficacy And Safety Of Standard Chemoradiation And Add-On Concurrent Cetuximab ± Consolidation Cetuximab |
Completed |
NCT01435252 |
Phase 2 |
Cetuximab |
16 |
Randomised Phase II Study of GM-CSF to Reduce Severity of Mucositis Caused by Accelerated Radiotherapy of Laryngeal Cancer |
Completed |
NCT00004256 |
Phase 2 |
|
17 |
RESILIENCE: Effect of Comprehensive Celecoxib Through Treatment for Advanced-Stage Head and Neck Cancer: A Randomized, Double-Blinded, Placebo-Controlled Trial |
Recruiting |
NCT04162873 |
Phase 2 |
Celecoxib |
18 |
Hypofractionated Proton Therapy for the Treatment of Head and Neck Cancer, The HEADLIGHT Study" |
Recruiting |
NCT05075980 |
Phase 2 |
Cisplatin |
19 |
Intensifying Radiation Treatment in Advanced/ Poor Prognosis Laryngeal, Hypopharyngeal (LH) and Oropharyngeal Cancers (OPC) Using PET -CT Based Dose Escalation Strategies ( INTELHOPE) |
Recruiting |
NCT02757222 |
Phase 1, Phase 2 |
|
20 |
A Phase 2 Study of Ipatasertib in Combination With Pembrolizumab for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck |
Recruiting |
NCT05172258 |
Phase 2 |
Ipatasertib |
21 |
A Phase II Trial of the Efficacy and Safety of the Combination of Cemiplimab and Low-Dose Paclitaxel and Carboplatin in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck |
Recruiting |
NCT04862650 |
Phase 2 |
Carboplatin;Paclitaxel |
22 |
Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing |
Recruiting |
NCT02734537 |
Phase 2 |
Cisplatin |
23 |
Immuno-Chemotherapy as Single Treatment Modality for Larynx Preservation (ICoLP) |
Recruiting |
NCT04030455 |
Phase 2 |
Carboplatin;Cisplatin;Docetaxel |
24 |
Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Patients With Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study |
Recruiting |
NCT05136196 |
Phase 2 |
Cabozantinib S-malate |
25 |
Induction Chemotherapy and Toripalimab Followed by Surgery or Radiotherapy for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma |
Recruiting |
NCT04995120 |
Phase 2 |
chemotherapy TP regimen combined with Toripalimab |
26 |
Induction Chemotherapy and Toripalimab Followed by Radiotherapy in Unresectable Laryngeal/Hypopharyngeal Carcinoma |
Recruiting |
NCT05420597 |
Phase 2 |
Toripalimab |
27 |
A Phase II Study of Sodium Thiosulfate (STS) for Prevention of Ototoxicity in Patients With Locally Advanced Squamous Cell Carcinoma of Head and Neck (SCCHN) Undergoing Concurrent Chemoradiation With Cisplatin |
Active, not recruiting |
NCT04541355 |
Phase 2 |
Cisplatin;Sodium Thiosulfate |
28 |
A Pilot, Double-Blind, Randomized, Two-Arm Crossover Study of Doxepin Versus Placebo for Esophagitis-Induced Pain in Patients Receiving Radiotherapy to the Thorax With or Without Chemotherapy |
Terminated |
NCT02062632 |
Phase 2 |
Doxepin Hydrochloride |
29 |
A Phase II Organ Preservation Trial Using Cetuximab and Radiation Therapy in Advanced Laryngeal Cancer Patients Who Have Responded to One Cycle of Induction Chemotherapy With Taxotere, Cisplatin, 5-Fluorouracil (TPF), and Cetuximab |
Terminated |
NCT00599131 |
Phase 2 |
Cisplatin;Cetuximab;5-Fluorouracil;Docetaxel |
30 |
Induction Chemotherapy With TPF Followed by Radioimmunotherapy With Cetuximab and Intensity Modulated Radiotherapy (IMRT) Plus Carbon Ion Boost for Locally Advanced Tumors of the Oro-, Hypopharynx and Larynx: TPF-C-HIT |
Terminated |
NCT01245985 |
Phase 2 |
|
31 |
Resistance Training and Physical Functioning in Head and Neck Cancer Patients |
Completed |
NCT01332682 |
Phase 1 |
|
32 |
Phase I Study of Bortezomib and Cetuximab Without or With Cisplatin in Combination With Radiation Therapy for Advanced Head and Neck Cancer |
Completed |
NCT01445405 |
Phase 1 |
Bortezomib (Velcade, PS-341);Cetuximab;Cisplatin |
33 |
Phase I/Ib Study of AKT Inhibitor Ipatasertib With Chemoradiation for Locally Advanced Head and Neck Cancer |
Recruiting |
NCT05172245 |
Phase 1 |
Cisplatin;Ipatasertib |
34 |
Phase I Trial of BAY 1895344 ATR Inhibitor Combined With Stereotactic Body Radiation Therapy and Pembrolizumab for Recurrent Head and Neck Squamous Cell Carcinoma |
Recruiting |
NCT04576091 |
Phase 1 |
Elimusertib |
35 |
Proton Image-Guided Radiation Assignment for Therapeutic Escalation Via Selection of Locally Advanced Head and Neck Cancer Patients [PIRATES] |
Recruiting |
NCT04870840 |
Phase 1 |
|
36 |
Olaparib Dose Escalation Trial in Patients Treated With Radiotherapy for Stage II-III Laryngeal and Stage II-III HPV-negative Oropharyngeal Squamous Cell Carcinoma |
Active, not recruiting |
NCT02229656 |
Phase 1 |
Olaparib |
37 |
Phase Ib Study of Pembrolizumab in Combination With Chemo Radiotherapy (CRT) for Locally-advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) |
Active, not recruiting |
NCT02586207 |
Phase 1 |
pembrolizumab (MK-3475);Cisplatin |
38 |
A Phase I Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer |
Active, not recruiting |
NCT03114462 |
Phase 1 |
|
39 |
Phase I Trial With Expansion Cohort of DNA-PK Inhibition and IMRT in Cisplatin-Ineligible Patients With Stage 3-4 Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) |
Suspended |
NCT04533750 |
Phase 1 |
Peposertib |
40 |
A Phase I Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Advanced Laryngeal Cancer |
Terminated |
NCT02464137 |
Phase 1 |
|
41 |
A Multicenter, Randomized, Case-control Study of Unilateral vs Bilateral Selective Neck Dissection for Clinically Negative Neck of Supraglottic Laryngeal Carcinoma |
Unknown status |
NCT03392220 |
|
|
42 |
Study of Previously Collected Blood and Tissue Samples From Patients With Nasopharyngeal Carcinoma,Laryngeal Carcinoma and Hypopharyngeal Carcinoma |
Unknown status |
NCT01171235 |
|
|
43 |
Effect of Perioperative ERAS Based Nursing Intervention on Hope Level of Patients With Laryngeal Cancer |
Unknown status |
NCT04174950 |
|
|
44 |
A Novel Modified Tracheo-Esophageal Voice Prosthesis for Total Laryngectomy Patients |
Unknown status |
NCT03039465 |
|
|
45 |
Development and Validation of Nomograms to Precisely Predict Conditional Risk of Survival for Patients With Laryngeal Cancer: a Single-institutional Study |
Unknown status |
NCT03747783 |
|
|
46 |
Development and Validation of Nomograms to Precisely Predict Conditional Risk of Recurrence for Patients With Laryngeal Cancer: a Single-institutional Study |
Unknown status |
NCT03595410 |
|
|
47 |
The Role of Stromal Cell-Derived Factor-1 (SDF-1)/CXC Chemokine Receptor 4 (CXCR4) in Metastasis of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma |
Unknown status |
NCT00174096 |
|
|
48 |
The Role of Lymphangiogenesis in Head and Neck Cancer Metastasis |
Unknown status |
NCT00173381 |
|
|
49 |
The Role of MMPs in the CXCL12-Induced Invasion of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma |
Unknown status |
NCT00302562 |
|
|
50 |
Thulium Contact Laser in the Treatment of Tumorous and Non-tumorous Laryngotracheal Stenosis |
Completed |
NCT02587546 |
|
|
|